SLC5A2 and type 2 diabetes mellitus: They found that, compared to other SGLT2 inhibitors (canagliflozin 100 mg, dapagliflozin 5 or 10 mg, and empagliflozin 10 or 25 mg), canagliflozin 300 mg significantly reduced HbA1c levels and fasting glucose in patients with T2DM.